Key result
IV amiodarone linked to reversible TdP in a patient with heart failure.
Case Report (n=1)
Amiodarone can induce Torsade de pointes, particularly in patients with heart failure taking digitalis, despite its generally low proarrhythmic risk.
Answers are grounded in this paper and cite their sources.
May prompt ECG monitoring for TdP in HF patients on IV amiodarone plus digitalis; case report leaves risk quantification open.
Dear Editor, Amiodarone is widely used to control and prevent the occurrence of cardiac arrhythmias in patients with severe heart failure. Although amiodarone, like other class III antiarrhythmic drugs, can cause QT-interval prolongation, the development of torsade de pointes (TdP) in patients taking amiodarone is rare [1]. When fatal ventricular arrhythmia occurs in a patient with severe heart failure who is being treated with amiodarone, it is important to determine whether the mechanism of ventricular arrhythmia was induced by that drug or by other causes of abnormal electrical activity in the heart. A 61-year-old woman with severe mitral valve regurgitation, atrial fibrillation, and heart failure under regular medical control presented with progressive acute decompensated heart failure. Mitral valve replacement (MVR) was suggested. The results of 12-lead electrocardiography revealed a QT interval of 450 ms and a corrected QT (QTc) interval of 439 ms. MVR surgery was successfully performed; however, amiodarone 300 mg administered as an intravenous bolus followed by 900 mg/day administered as an intravenous drip was required to treat a frequently occurring premature ventricular contraction. After 2 days of amiodarone therapy, 12-lead electrocardiography revealed a QT interval of 520 ms and a QTc interval of 580 ms, respectively (Fig. 1A). A sustained, wide QRS complex tachycardia with shifting axis was noted (Fig. 1B). A diagnosis of TdP was made based on the presence of prolonged QT intervals with shifting axis. Administration of amiodarone was, therefore, discontinued. Follow-up 12-lead electrocardiography performed 5 days after discontinuation of amiodarone revealed a QT interval of 440 ms and a QTc interval of 519 ms and no evidence of a sustained wide QRS complex tachycardia. (A) The 12-lead electrocardiogram after amiodarone therapy. The QT interval is 520 ms and the corrected QT interval is 580 ms. (B) A wide QRS tachycardia is noted after aminodarone therapy recorded by bed-side eletrocardiogram monitor. TdP is diagnosed based on the presence of prolongation of QT intervals and shifting axis. TdP is a lethal polymorphic ventricular tachycardia characterized by prolonged QT intervals. Although amiodarone is a class III antiarrhythmic agent, it has multiple channel blocking effects, including blockade of the fast sodium channel, the slow calcium channel, the delayed outward potassium channels, and noncompetitive β-adrenergic antagonism. Amiodarone therapy contributes to approximately 2% of cases of incident proarrhythmic events and to approximately 0.7% of cases of TdP [1]. The low incidence of amiodarone-induced TdP may be because amiodarone results in more homogeneous repolarization across ventricular cells than other class III antiarrhythmic drugs [2]. Older age, female sex, hypokalemia, and combined use of amiodarone with digitalis therapy are independent risk factors for TdP occurrence in patients under amiodarone therapy [3]. In our patient, amiodarone was used to treat premature ventricular contraction and digoxin was used to treat atrial fibrillation and heart failure. Combination therapy comprising digitalis drugs and amiodarone can trigger bradycardia or a pause that can trigger TdP [4]. In addition, digoxin can inhibit the sodium/potassium pump, which can indirectly enhance the sodium/calcium exchanger function, leading to intracellular calcium accumulation and early afterdepolarizations [5]. In conclusion, amiodarone is an effective and safe antiarrhythmic agent. Although the incidence of TdP is low, amiodarone can induce TdP in patients with hypokalemia or hypomagnesaemia and in patients who take the drug in combination with digitalis therapy.
No takes yet. Share an insight, caveat, or question.
Jhuo et al. (2013) conducted a case report in Heart failure, atrial fibrillation, and severe mitral valve regurgitation (n=1). Amiodarone was evaluated on Torsade de pointes (TdP). Intravenous amiodarone therapy induced Torsade de pointes in a 61-year-old woman with heart failure, which resolved after drug discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: